title: Deletions of the derivative chromosome 9 do not influence the response and the outcome of chronic myeloid leukemia in early chronic phase treated with imatinib mesylate: GIMEMA CML Working Party analysis.
abstract: OBJECTIVE
  Deletions of the derivative chromosome 9 [der(9)] have been associated with a poor prognosis in chronic myeloid leukemia (CML) across different treatment modalities. In the imatinib era, the prognostic impact of der(9) deletions has been evaluated mainly in patients with late chronic-phase (CP) CML, giving partially conflicting results. Few data are available in the early CP setting. For this reason, in 2006, the European LeukemiaNet recommendations still considered der(9) deletions as a candidate adverse prognostic factor and required a careful monitoring of the patient.
  
  
  METHODS
  To investigate the prognostic value of der(9) deletions in early CP CML, we performed an analysis of three prospective imatinib trials of the Italian Group for Hematological Malignancies of the Adult (GIMEMA) CML Working Party.
  
  
  RESULTS
  A fluorescent in situ hybridization (FISH) analysis of bone marrow cells was performed at diagnosis; der(9) deletions were detected in 60 (12%) of 521 evaluable patients. At 60 months, the cumulative incidence of complete cytogenetic response and major molecular response-and the probability of event-free survival, failure-free survival, progression-free survival, and overall survival-in patients with and without deletions were not statistically different.
  
  
  CONCLUSIONS
  Our data strongly support the notion that, when investigated by FISH, der(9) deletions are not a poor prognostic factor in patients with early CP CML treated with imatinib.
authors.affiliation: Department of Hematology and Oncological Sciences, Sant'Orsola-Malpighi Hospital, University of Bologna, Via Massarenti 9, Bologna, Italy.
authors.forename: Fausto
authors.initials: F
authors.lastname: Castagnetti
authors.forename: Nicoletta
authors.initials: N
authors.lastname: Testoni
authors.forename: Simona
authors.initials: S
authors.lastname: Luatti
authors.forename: Giulia
authors.initials: G
authors.lastname: Marzocchi
authors.forename: Marco
authors.initials: M
authors.lastname: Mancini
authors.forename: Simonetta
authors.initials: S
authors.lastname: Kerim
authors.forename: Emilia
authors.initials: E
authors.lastname: Giugliano
authors.forename: Francesco
authors.initials: F
authors.lastname: Albano
authors.forename: Antonio
authors.initials: A
authors.lastname: Cuneo
authors.forename: Elisabetta
authors.initials: E
authors.lastname: Abruzzese
authors.forename: Bruno
authors.initials: B
authors.lastname: Martino
authors.forename: Francesca
authors.initials: F
authors.lastname: Palandri
authors.forename: Marilina
authors.initials: M
authors.lastname: Amabile
authors.forename: Ilaria
authors.initials: I
authors.lastname: Iacobucci
authors.forename: Giuliana
authors.initials: G
authors.lastname: Alimena
authors.forename: Fabrizio
authors.initials: F
authors.lastname: Pane
authors.forename: Giovanni
authors.initials: G
authors.lastname: Martinelli
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Saglio
authors.forename: Michele
authors.initials: M
authors.lastname: Baccarani
authors.forename: Gianantonio
authors.initials: G
authors.lastname: Rosti
mesh_terms: D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D001549:Benzamides; D002899:Chromosomes, Human, Pair 9 / Q000235:genetics*; D020732:Cytogenetic Analysis; D018572:Disease-Free Survival; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D017353:Gene Deletion; D006801:Humans; D000068877:Imatinib Mesylate; D017404:In Situ Hybridization, Fluorescence; D007558:Italy; D053208:Kaplan-Meier Estimate; D015466:Leukemia, Myeloid, Chronic-Phase / Q000188:drug therapy* / Q000235:genetics* / Q000401:mortality; D016015:Logistic Models; D008297:Male; D020714:Maximum Tolerated Dose; D008875:Middle Aged; D015999:Multivariate Analysis; D010879:Piperazines / Q000008:administration & dosage* / Q000009:adverse effects; D011336:Probability; D011379:Prognosis; D011446:Prospective Studies; D011743:Pyrimidines / Q000008:administration & dosage* / Q000009:adverse effects; D012016:Reference Values; D020133:Reverse Transcriptase Polymerase Chain Reaction; D018570:Risk Assessment; D012720:Severity of Illness Index; D018709:Statistics, Nonparametric; D016019:Survival Analysis; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate